Qube Research & Technologies (QRT)
ATXI

Qube Research & Technologies (QRT)’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-632
Closed -$55K – 3129
2022
Q4 		$55K Buy
+632
New +$115K ﹤0.01% 2124

Other funds holding ATXI

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
IWP
Icon Wealth Partners Houston, Texas $880M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ATXI Position: Q1 2023 in Review

Qube Research & Technologies (QRT) sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q1 2023, closing a stake of 632 shares — an estimated $55K sold.

Qube Research & Technologies (QRT) first reported a position in ATXI in Q4 2022 and held it in 1 quarter. The position peaked at $55K in Q4 2022. 13 funds tracked by Wall St. Rank hold ATXI as of Q1 2023.

  • Qube Research & Technologies (QRT) reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 632 Avenue Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $55K.
  • Qube Research & Technologies (QRT) first reported a position in Avenue Therapeutics, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Qube Research & Technologies (QRT)'s Avenue Therapeutics, Inc. Common Stock position peaked at $55K in Q4 2022.
  • 13 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2023, filed 15 May 2023.